06/2022 – 02/2024 | Graduate Researcher (First Author Project)
Project: Identifying ELOB as a Novel Regulator of Mitochondrial Function and Radiosensitivity in TNBC
Supervisor: Dr. Zhichao Fu, The 900th Hospital of the Joint Logistic Support Force (FJMU)
Publication: Li, G., et al. Enhancing radiosensitivity in triple-negative breast cancer through targeting ELOB. Breast Cancer (2024). https://doi.org/10.1007/s12282-024-01554-w
-
Clinical Significance & Bioinformatics: Identified Elongin B (ELOB) as a key prognostic marker in Triple-Negative Breast Cancer (TNBC) by analyzing TCGA transcriptomic data, discovering that high ELOB expression correlates with poor overall survival specifically in patients receiving radiotherapy.
-
Genome Editing & Phenotyping: Leveraged CRISPR-Cas9 technology to generate stable ELOB-knockout (KO) TNBC cell lines. Demonstrated through SRB and colony formation assays that ELOB depletion significantly sensitizes TNBC cells to ionizing radiation without affecting baseline viability or migration.
-
Subcellular Mechanistic Discovery: Deciphered the non-canonical role of ELOB in mitochondria. Used cell fractionation, immunofluorescence (confocal microscopy), and Proteinase K protection assays to validate ELOB’s dual localization in both the nucleus and mitochondrial matrix.
-
Metabolic Profiling: Conducted functional metabolic assays using the Seahorse XFe96 Analyzer (Mito Stress Test), proving that ELOB is indispensable for maintaining mitochondrial oxygen consumption rates (OCR) and respiratory capacity.
-
Rescue & Molecular Pathways: Employed molecular cloning and lentiviral transduction to express MTS/NLS-tagged ELOB constructs, confirming that mitochondrial ELOB, rather than nuclear ELOB, restores radioresistance. Further elucidated that ELOB regulates the expression of 13 mtDNA-encoded genes and the activity of respiratory chain complexes (I-V).
-
Conclusion: Established the ELOB-mtDNA-Metabolism axis as a critical determinant of radioresistance, proposing ELOB inhibition as a potent strategy to overcome therapeutic resistance in TNBC.
临床意义与生物信息学:通过分析TCGA转录组数据,将Elongin B(ELOB)鉴定为三阴性乳腺癌(TNBC)的关键预后标志物,发现高ELOB表达与接受放疗患者的较差总生存期显著相关。
基因组编辑与表型分析:利用CRISPR-Cas9技术构建稳定的ELOB基因敲除(KO)TNBC细胞系;通过SRB和克隆形成实验证实,ELOB缺失可显著增强TNBC细胞对电离辐射的敏感性,且不影响基线活力和迁移能力。
亚细胞机制发现:解析ELOB在线粒体中的非经典功能。采用细胞分级分离、免疫荧光(共聚焦显微镜)及蛋白酶K保护实验,验证ELOB在细胞核和线粒体基质中的双重定位。
代谢 profiling:使用Seahorse XFe96分析仪进行功能性代谢测定(线粒体压力测试),证明ELOB对于维持线粒体耗氧率(OCR)和呼吸能力不可或缺。
回补实验与分子通路:通过分子克隆和慢病毒转导表达MTS/NLS标记的ELOB构建体,证实线粒体ELOB(而非核ELOB)可恢复放射抵抗性;进一步阐明ELOB调控13个线粒体DNA编码基因的表达以及呼吸链复合物(I-V)的活性。
结论:确立ELOB-mtDNA-代谢轴为放射抵抗性的关键决定因素,提出抑制ELOB是克服TNBC治疗耐药性的有效策略。
用什么方法 做什么事情 取得了什么结果
设计并在癌细胞系上执行了 CRISPR 基因编辑实验,确定了两个新的基因靶点,将治疗效果提高了 30%。
利用tcga数据库研究elob和tnbc患者的预后关系,发现在放疗的tnbc病人中,elob高表达的病人预后更差。
利用CRISPR技术在tnbc细胞系中敲低elob基因,使用Sulforhodamine B assay检测敲低后的细胞放疗敏感性增加了,使用Seahorse线粒体压力测试检测测敲低后的细胞线粒体呼吸降低了,使用qpcr确定敲低后的tnbc细胞mtDNA表达下降,进一步导致复合体I、III、IV和V的活性显著下降。
利用免疫荧光以及细胞组分分离后wb,确定elob的细胞定位有两处,利用慢病毒分别转导核定位的elob和线粒体定位的elob,验证是线粒体中的elob加强了细胞呼吸,并让细胞放疗抵抗性增加。
得出结论:靶向ELOB可有效调节线粒体功能,从而增强TNBC细胞的放射敏感性
-
旨在探究靶向Elongin B(ELOB)提高三阴性乳腺癌(TNBC)放疗疗效的潜力
-
使用磺酰罗丹明B(SRB)实验,比较ELOB基因敲除(KO)TNBC细胞与表达ELOB的TNBC细胞之间的放射敏感性
-
采用免疫荧光、细胞分级分离和蛋白质印迹(Western blot)分析,检测ELOB在细胞核和线粒体中的亚细胞定位
-
利用慢病毒介导的转导,分别评估线粒体ELOB对mtDNA表达及线粒体呼吸链复合物的影响
-
得出结论:靶向ELOB可有效调节线粒体功能,从而增强TNBC细胞的放射敏感性
根据你要求的 APR (Action-Project/Problem-Result) 模式,我为你重新组织了这段研究经历。这种写法能够非常清晰地向欧洲导师展示你的主动性(Action)、技术熟练度(Project/Skill)以及科研产出(Result)。
Research Experience: ELOB-Mediated Radiosensitivity in TNBC
利用tcga数据库研究elob和tnbc患者的预后关系,发现在放疗的tnbc病人中,elob高表达的病人预后更差。
- Analyzed TNBC patient cohorts from the TCGA database using bioinformatic tools to evaluate the prognostic value of Elongin B (ELOB), revealing a significant correlation between high ELOB expression and poor overall survival specifically in patients undergoing radiotherapy.
- 分析了TCGA数据库中的TNBC患者队列,利用生物信息学工具评估Elongin B (ELOB)的预后价值,揭示出高ELOB表达与接受放疗患者的较差总生存期之间存在显著相关性。
(Action: Analyzed | Project: TCGA data & prognosis | Result: Identified ELOB as a radiotherapy-specific prognostic marker)
利用CRISPR技术在tnbc细胞系中敲低elob基因,使用Sulforhodamine B assay检测敲低后的细胞放疗敏感性增加了,使用Seahorse线粒体压力测试检测测敲低后的细胞线粒体呼吸降低了,使用qpcr确定敲低后的tnbc细胞mtDNA表达下降,进一步导致复合体I、III、IV和V的活性显著下降。
-
Engineered stable ELOB-knockout TNBC cell lines via CRISPR-Cas9 technology and assessed their phenotype through Sulforhodamine B (SRB) assays and Seahorse XFe96 Mito Stress Tests, demonstrating that ELOB depletion significantly enhances radiosensitivity and impairs mitochondrial oxygen consumption.
-
通过CRISPR-Cas9技术构建稳定的ELOB基因敲除TNBC细胞系,并通过磺酰罗丹明B(SRB)实验和Seahorse XFe96线粒体压力测试评估其表型,证实ELOB缺失显著增强放射敏感性并损害线粒体耗氧量。
(Action: Engineered & Assessed | Project: CRISPR knockout & functional assays | Result: Validated ELOB's role in radioresistance and respiration) -
Quantified mitochondrial DNA (mtDNA) expression and the activity of respiratory chain complexes (I, III, IV, V) using RT-qPCR and enzymatic microplate assays, elucidating that ELOB deficiency leads to a widespread reduction in mtDNA-encoded genes and subsequent mitochondrial dysfunction.
(Action: Quantified | Project: qPCR & Complex activity assays | Result: Uncovered the molecular mechanism of ELOB-mediated mitochondrial regulation)
- 利用RT-qPCR和酶标板比色法定量检测线粒体DNA(mtDNA)表达及呼吸链复合物(I、III、IV、V)的活性,阐明ELOB缺陷导致mtDNA编码基因广泛下调,进而引起线粒体功能障碍。
(动作:定量检测 | 项目:qPCR与复合物活性实验 | 结果:揭示了ELOB介导线粒体调控的分子机制)
- Characterized the subcellular localization of ELOB via confocal immunofluorescence and cell fractionation, and executed rescue experiments using lentiviral-mediated transduction of NLS- or MTS-tagged ELOB constructs, validating that it is the mitochondrial pool of ELOB, rather than the nuclear pool, that drives respiration and radioresistance.
(Action: Characterized & Executed | Project: Protein localization & Lentiviral rescue | Result: Confirmed mitochondrial ELOB as the primary therapeutic target)
- 通过共聚焦免疫荧光和细胞分级分离表征ELOB的亚细胞定位,并利用慢病毒介导的NLS或MTS标签ELOB构建体转导执行回补实验,验证驱动呼吸和放射抵抗的是线粒体ELOB而非核ELOB。
(动作:表征与执行 | 项目:蛋白定位与慢病毒回补 | 结果:确认线粒体ELOB是主要治疗靶点)
利用免疫荧光以及细胞组分分离后wb,确定elob的细胞定位有两处,利用慢病毒分别转导核定位的elob和线粒体定位的elob,验证是线粒体中的elob加强了细胞呼吸,并让细胞放疗抵抗性增加。
得出结论:靶向ELOB可有效调节线粒体功能,从而增强TNBC细胞的放射敏感性
- Established ELOB as a pivotal regulator of mitochondrial homeostasis in TNBC, concluding that targeting the ELOB-mtDNA axis effectively sensitizes tumors to radiotherapy, providing a novel theoretical basis for improving TNBC treatment outcomes.
(Action: Established | Project: Mechanistic link | Result: Proposed a new therapeutic strategy for TNBC)
确立ELOB为TNBC线粒体稳态的关键调控因子,得出结论:靶向ELOB-mtDNA轴可有效增敏肿瘤放疗,为改善TNBC治疗结局提供了新的理论依据。
修改要点解析 (Why this APR works):
-
Action (动词选择):
- 使用了 Analyzed (分析), Engineered (构建/工程化), Quantified (定量), Characterized (表征), Established (确立)。这些词汇比简单的 "did" 或 "used" 更有力度,体现了你的专业度。
-
Project/Problem (技能与方法):
- 在每一句中都嵌入了核心技术点:TCGA, CRISPR-Cas9, SRB assay, Seahorse XFe96, RT-qPCR, Confocal microscopy, Lentiviral transduction。
- 这直接告诉导师:你不需要培训,你已经掌握了这些高级技能。
-
Result (产出与影响):
- 不只是说“得到了结果”,而是说“揭示了 (revealing)”、“论证了 (demonstrating)”、“阐明了 (elucidating)”。
- 特别是提到了 "specifically in patients undergoing radiotherapy" 和 "mitochondrial-specific ELOB",这显示了你对课题细节的严谨把控。
建议: 在 CV 中,你可以将这些 Action Verbs(如 Analyzed, Engineered)加粗,让阅读简历的教授在扫描页面时瞬间抓取到你的能力关键词。